The world’s first all-integrated instrument based on droplet microfluidics tech with the ability to detect and select biological cells such as therapeutic antibody-producing cells like monoclonal antibodies, cancer cells, rare immune cells, stem cells and fragile cells that are difficult to manipulate with classical techniques such as flow cytometers (FACS: “Fluorescence-activated cell sorter”) and multiwell plates.
LiveDrop has raised €2.3M across 1 funding round from 3 investors, most recently a round in May 2022. Based in Brussels, Belgium; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-05-09 | Other | €2.3M |
| Innovation Fund,Noshaq the Liège,W.IN.G. |
| View deal → |
